<DOC>
	<DOC>NCT01917643</DOC>
	<brief_summary>This study is intended to evaluate treatment effectiveness with budesonide/formoterol (BFC) and tiotropium tromide in patients new to ICS/LABA combination and LAMA therapies.</brief_summary>
	<brief_title>Comparative Effectiveness of Symbicort vs. Spiriva Among COPD Patients</brief_title>
	<detailed_description>Using US claims data from the HealthCore Integrated Research Environment, COPD patients â‰¥40 years old initiating BFC or tiotropium between 3/1/2009-2/28/2012 and considered at risk for a future exacerbation were identified and followed for 12 months.</detailed_description>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Continuous health plan enrollment for 12 months before and after index Rx At least one prescription fill for BFC or tiotropium bromide during intake period, and naive to ICS/LABA combination or LAMA therapies in year prior to first prescription claim. COPD diagnosis, and aged 40 years of age at time of first prescription At risk population for COPD exacerbations ICS/LABA combination or LAMA therapy during preindex period Patients with prescription claim for budesonide/formoterol and tiotropium bromide on the same day Patients diagnosed with cancer Patients with longterm OCS medication use during preindex period</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>COPD, Comparative Effectiveness, Symbicort</keyword>
</DOC>